Beyond CSF albumin, a study by Ivan Kmezic and colleagues provided preliminary evidence supporting beta-trace protein (BTP) levels in CSF and plasma as potential biomarkers for CIDP and GBS (29). This evidence concerns the gene PTGDS and chronic inflammatory demyelinating polyradiculoneuropathy.